Browse drugs

…ith filters for RCTs. We restricted our analysis to ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab …

…l be ‘lost’ on resistant pts (~85%) due to receiving at least 2 ICI cycles to enable response evaluation. Furthermore, the ‘non-res…

…rolled in a first-line phase II trial of the anti-PD-1 antibody nivolumab.13 Together, these data suggest then an immunologically enriche…

…gimen start.Results Of 46 evaluable patients, 24 (52%) received ICI monotherapy and 22 (48%) received ICI-based combinations. Six p…

…lick AC, Jiang J, Avila A, … Margolin K. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. The New England Journal of…

… types, including colorectal tumors. Combinatorial treatment of ICI with anti-CD40 agonist antibody enhanced TIL clonal diversity, …

…ALB2) in altering inflammatory signals in response to PARPi and ICi. This data may guide the clinical development of such combinati…

…ssociated with differential response to targeted inhibitors and ICi. The mesenchymal-like cell state elicits an invasive phenotype …

…The introduction of immune checkpoint inhibitors (ICI) has revolutionized the treatment of many solid tumors includin…

…Background Immune checkpoint inhibitors (ICI) are the current standard of care for patients with recurrent/m…

… total, we sequenced 13,914 TILs from EO771 tumors treated with ICI monotherapy or dual checkpoint blockade. By unsupervised cluste…

…e in ~40% of patients. First-line immune checkpoint inhibitors (ICI) that block the programmed cell death protein-1/programmed deat…